Biosimilar Antibodies

Anti-PAR2 is a monoclonal antibody specifically targeting Protease-Activated Receptor 2 (PAR2). This receptor is a key player in various biological processes, including inflammation and pain perception, making this antibody an essential tool for research in these areas. It is designed for use in a range of applications such as Western blotting, immunohistochemistry, and flow cytometry, providing researchers with a reliable means to study PAR2 expression and function in different biological contexts.

Anti-TYRO3 (ELB031) is a monoclonal antibody specifically designed to target and bind to the TYRO3 and MERTK receptors. This antibody is produced for the purpose of studying the signaling pathways and biological functions associated with these receptor tyrosine kinases, which are implicated in various cellular processes including cell survival, migration, and differentiation. Anti-TYRO3 (ELB031) is ideal for use in research applications focused on cancer, immune regulation, and neurological diseases where TYRO3 and MERTK play critical roles.

M6903 is a humanized monoclonal IgG2 antibody that specifically targets T cell immunoglobulin and mucin domain-3 (TIM-3), exhibiting a dissociation constant (K_D) of 2.3 nM for human TIM-3. This antibody effectively binds to TIM-3, inhibiting its interaction with key ligands including phosphatidylserine (PtdSer), carcinoembryonic antigen cell adhesion-related molecule 1 (CEACAM1), and galectin 9 (Gal-9). By blocking these interactions, M6903 mitigates TIM-3-mediated suppression of T cell activity, thereby activating antigen-specific T cells and enhancing anti-tumor immune responses. This antibody is particularly valuable for research focused on cancer immunology and the development of immunotherapeutic strategies.

Obiltoxaximab (ETI 204) is a highly potent monoclonal antibody targeting the protective antigen (PA) component of Bacillus anthracis, the bacterium responsible for anthrax. This antibody is critical in disrupting the assembly of anthrax toxin, thereby preventing the intoxication of target cells. Demonstrating efficacy in animal models, Obiltoxaximab enhances survival rates and impedes the peripheral dissemination of the bacteria. It is primarily utilized in research focused on inhalational anthrax, as well as associated bacteremia and toxemia. This makes Obiltoxaximab an essential tool for studies aimed at understanding and mitigating the pathogenic mechanisms of anthrax.

Becotatug (JMT-101) is an IgG1 monoclonal antibody specifically designed to target the Epidermal Growth Factor Receptor (EGFR). This antibody can be conjugated with Afatinib and Osimertinib, enabling its use as a synthetic antibody-drug conjugate (ADC) for targeted cancer therapy. This feature allows for the precise delivery of therapeutic agents to EGFR-expressing cells, potentially enhancing treatment efficacy and reducing off-target effects.

Acrixolimab is a humanized IgG4-κ monoclonal antibody designed to selectively target PD-1 (Programmed Death-1). This antibody is engineered to bind with high specificity to the PD-1 receptor, thereby modulating immune responses and enhancing immune cell activity. Acrixolimab is primarily used in research focused on immunotherapy and the study of immune checkpoint pathways in oncology.

The Anti-TGFb1 Antibody is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting Transforming Growth Factor Beta 1 (TGFb1). This antibody comprises a human IgG1 type heavy chain and a human kappa type light chain, with an approximate molecular weight of 145 kDa. For isotype control, Human IgG1 kappa, Isotype Control is recommended. This product is ideal for research applications focusing on the biological activities and regulatory mechanisms of TGFb1.

Rinatabart is a human monoclonal antibody of the IgG1κ subtype designed to target FOLR1. For experimental control purposes, it is recommended to use Human IgG1 kappa as an isotype control. This specificity makes Rinatabart suitable for research focused on the biological pathways and diseases associated with the FOLR1 receptor.

Cepeprubart is a human IgG2 κ monoclonal antibody specifically targeting SELPLG. For accurate experimental control, it is recommended to use Human IgG2 kappa as an isotype control.

Modotuximab (DS 1024) is a chimeric monoclonal antibody of the IgG1κ isotype, designed to specifically target the human Epidermal Growth Factor Receptor (EGFR). This antibody recognizes non-overlapping epitopes located on domain III of the EGFR protein, a region preserved in the EGFR variant III (EGFRvIII). Modotuximab demonstrates potent antitumor activity in vivo, making it a valuable tool for research in cancer biology and therapeutic development.

Anti-YB-1 Antibody (21A3) is a chimeric mouse IgG1 monoclonal antibody specifically designed to target human Y-box binding protein 1 (YB-1). For accurate experimental control, it is recommended to use Mouse IgG1 kappa Isotype Control alongside this antibody.

Rolinsatamab is a chimeric monoclonal antibody of the IgG1κ subtype, specifically designed to target the prolactin receptor (PRLR). This antibody can be conjugated to the pyrrolobenzodiazepine (PDB) dimer SGD-1882 through a cleavable maleimidocaproyl linker, creating the antibody-drug conjugate known as Rolinsatamab talirine. This conjugate features an average of two site-specific drug attachments at engineered cysteines (S239C). The linker incorporates a valine-alanine dipeptide, which serves as a cleavage site for cathepsin B, facilitating the release of the cytotoxic agent upon entry into targeted cells. Rolinsatamab talirine is primarily utilized in therapeutic applications where precise delivery of cytotoxic agents to cells expressing PRLR is required.

The Anti-CDH1/E-cadherin/CD324 Antibody is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells. It is designed to specifically target CDH1, also known as E-cadherin or CD324, a critical protein involved in cell-cell adhesion and cancer metastasis regulation. This antibody is comprised of a human IgG1 heavy chain and a human kappa light chain, and exhibits a predicted molecular weight of 146.6 kDa. For experimental control purposes, Human IgG1 kappa, Isotype Control is recommended. This antibody is applicable for use in various immunodetection techniques to study E-cadherin expression in pathological samples or in research focused on epithelial cell biology and oncology.